Atopic dermatitis represents a complex and multidimensional interaction that represents potential fields of preventive and therapeutic management. In addition to the treatment armamentarium available for atopic dermatitis, novel drugs targeting significant molecular pathways in atopic dermatitis biologics and small molecules are also being developed given the condition’s complex pathophysiology. While most of the patients are expecting better efficacy and long-term control, the response to these drugs would still depend on numerous factors such as complex genotype, diverse environmental triggers and microbiome-derived signals, and, most importantly, dynamic immune responses. This review article highlights the challenges and the recently developed pharmacological agents in atopic dermatitis based on the molecular pathogenesis of this condition, creating a specific therapeutic approach toward a more personalized medicine.
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Lichen planus pigmentosus [LPP] is a condition characterized by persistent and asymptomatic brownish-black to blue or purple-gray pigmentation, predominantly in the face and sun-exposed areas, commonly in dark-skinned individuals. Several clinical variants of LPP have been reported. However, the ichthyosiform type of LPP has not been reported. We present a 19‑year‑old male who presented with a 7-year history of asymptomatic grayish macules, patches with fine scales on the face, trunk and upper extremities and grayish plaques with thick, “ichthyosiform” scales on the lower extremities. Diagnosis of LPP was proven by histopathological finding on both the macular and ichthyosiform plaques. CD68 stain highlights the same density of pigment-laden macrophages in both the gray macule and the ichthyosiform plaque. The cause of LPP is unknown. Transcription factor anomalies may play a role in increased keratinization of lichen planus lesion. It can be assumed that the mechanism of the altered distribution of keratinization may occur on the ichthyosiform lesions in this patient. The terminology “ichthyosiform lichen planus pigmentosus” is hereby proposed to be added to the clinical variants of LPP.
30 September 2025 in Journal of Asia Pacific Aesthetic Sciences
Tattoos are widely used for cosmetic and therapeutic purposes; however, they may lead to adverse reactions. Tattoo allergies can have a substantial impact on the skin and the patient’s quality of life. Managing such allergies, particularly in older tattoos containing complex pigments, presents a significant therapeutic challenge. We report the case of a 60-year-old female with a persistent tattoo allergy. Initial treatments with corticosteroids and immunomodulators provided only temporary relief. She subsequently underwent six monthly sessions of Q-switched Neodymium:Yttrium-Aluminium-Garnet (Nd:YAG) laser tattoo removal, which resulted in marked pigment lightening and sustained symptom improvement without adverse effects. This case highlights the efficacy and tolerability of Q-switched Nd:YAG laser therapy as a viable long-term treatment for tattoo allergy.
31 August 2023 in Journal of Asia Pacific Aesthetic Sciences
Establishing a definite diagnosis for facial hyperpigmentation and pigmentary lesions in skin of color often poses challenges as they are frequently difficult to differentiate. Therefore, it becomes necessary to correlate history, clinical findings, dermoscopy, and histopathology to accurately identify and diagnose these conditions. We report a case of a 51-year-old Filipino man with a six-year history of asymptomatic pigmentation with a rough surface on forehead, cheeks, chin and neck. He also reported enlargement of the nose, earlobes, glabellar area and the chin. Dermoscopy and histopathology confirmed the diagnosis of acanthosis nigricans and phymatous rosacea. The coexistence of severe acanthosis nigricans and phymatous rosacea in skin of color has rarely been reported.
30 October 2026 in Journal of Asia Pacific Aesthetic Sciences
The increasing demand for bioremodelling in aesthetic practice has highlighted the need for standardised anatomical frameworks to ensure reproducible and safe treatment outcomes. This manuscript presents a review of an injection-point framework that specifically targets the retinacula cutis (RC) and retaining ligaments (RL) to enhance soft-tissue support. These anatomical structures form a continuous multifibrillar network that compartmentalises facial fat and distributes mechanical forces across tissues. By stimulating both papillary and reticular fibroblasts, targeted injections may promote the production of collagen and elastin, thereby reinforcing the extracellular matrix (ECM) and improving skin firmness. Ultimately, this framework serves as a reproducible foundation for clinicians to achieve more precise, anatomically sound facial rejuvenation.